等待开盘 10-09 09:30:00 美东时间
-0.790
-2.99%
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions intended to support cancer centers and clinical laboratories. Both solutions detect ci...
09-24 18:36
Biodesix announced advancements in tumor-informed and tumor-naïve MRD solutions to detect circulating tumor DNA (ctDNA) for cancer monitoring. The tumor-informed solution, developed with Bio-Rad, uses Droplet Digital PCR for ultra-sensitive detection. The tumor-naïve solution, in collaboration with Thermo Fisher, employs methylated ctDNA detection via next-generation sequencing. Both aim to enhance sensitivity and patient access, with data presen...
09-24 10:00
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-22 21:50
A group of U.S. small-cap stocks is flashing A+ momentum grades in the latest quantitative screen, with several names posting triple-digit gains year to date. Seeking Alpha's Quant Momentum Grade meas...
09-17 21:55
Biodesix's Vice President of Quality and Regulatory Affairs, Brianna Phillips, will present at the RAPS and SOCRA Annual Meetings, showcasing the company's QA/RA excellence. Under her leadership, Biodesix has achieved significant certifications and successful audits, enhancing its diagnostic blood tests for lung nodule patients. Phillips also contributes to industry education and leadership, aiming to advance patient care and outcomes.
09-14 20:01
Biodesix, Inc. announced that its leadership team will participate in three upcoming investor conferences in New York: the 10th Annual BIG10 Conference on September 10, the 28th Annual H.C. Wainwright Global Investment Conference on September 15, and the 5th Annual Roth Healthcare Opportunities Conference on September 29, featuring a panel discussion on MRD monitoring in solid tumors led by Gary Pestano, Ph.D.
09-03 10:00
Biodesix, Inc. (($BDSX)) has held its Q2 earnings call. Read on for the main hi...
08-17 08:23
今日重点评级关注:HC Wainwright & Co.:维持Innate Pharma"买入"评级,目标价从5美元升至7美元;HC Wainwright & Co.:维持Immix Biopharma"买入"评级,目标价从20美元升至25美元
08-11 11:45
今日重点评级关注:康托·菲茨杰拉德:维持EyePoint"超配"评级,目标价从47美元升至55美元;伯恩斯坦:维持Figure Technology"跑赢大市"评级,目标价从67美元升至70美元
08-07 13:41
HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $26 to $27.
08-07 02:34